FI973055L - Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi - Google Patents

Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi Download PDF

Info

Publication number
FI973055L
FI973055L FI973055A FI973055A FI973055L FI 973055 L FI973055 L FI 973055L FI 973055 A FI973055 A FI 973055A FI 973055 A FI973055 A FI 973055A FI 973055 L FI973055 L FI 973055L
Authority
FI
Finland
Prior art keywords
adenoviruses
cells
recombinant dna
producing recombinant
producing
Prior art date
Application number
FI973055A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973055A0 (fi
FI973055A7 (fi
Inventor
Jean-Francois Dedieu
Martine Latta
Cecile Orsini
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27253011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI973055(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9500747A external-priority patent/FR2729674B1/fr
Priority claimed from FR9506532A external-priority patent/FR2741891B1/fr
Priority claimed from FR9510541A external-priority patent/FR2738575B1/fr
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI973055A0 publication Critical patent/FI973055A0/fi
Publication of FI973055A7 publication Critical patent/FI973055A7/fi
Publication of FI973055L publication Critical patent/FI973055L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
FI973055A 1995-01-20 1996-01-19 Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi FI973055L (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9500747A FR2729674B1 (fr) 1995-01-20 1995-01-20 Cellules pour la production d'adenovirus recombinants
FR9506532A FR2741891B1 (fr) 1995-06-01 1995-06-01 Cellules pour la production d'adenovirus recombinants
FR9510541A FR2738575B1 (fr) 1995-09-08 1995-09-08 Cellules pour la production d'adenovirus recombinants
PCT/FR1996/000088 WO1996022378A1 (fr) 1995-01-20 1996-01-19 Cellules pour la production d'adenovirus recombinants

Publications (3)

Publication Number Publication Date
FI973055A0 FI973055A0 (fi) 1997-07-18
FI973055A7 FI973055A7 (fi) 1997-07-18
FI973055L true FI973055L (fi) 1997-07-18

Family

ID=27253011

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973055A FI973055L (fi) 1995-01-20 1996-01-19 Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi

Country Status (15)

Country Link
US (1) US6127175A (de)
EP (1) EP0805868A1 (de)
JP (1) JPH11504502A (de)
KR (1) KR100510822B1 (de)
AU (1) AU717253B2 (de)
BR (1) BR9606971A (de)
CA (1) CA2210168A1 (de)
CZ (1) CZ294969B6 (de)
FI (1) FI973055L (de)
HU (1) HU222191B1 (de)
IL (1) IL116816A (de)
MX (1) MX9704552A (de)
NO (1) NO320382B1 (de)
SK (1) SK99097A3 (de)
WO (1) WO1996022378A1 (de)

Families Citing this family (390)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710288B1 (de) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenovirale vektoren für die behandlung der hämophilie
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6730662B1 (en) 1996-07-05 2004-05-04 Mcgill University Adenovirus E4 proteins for inducing cell death
DE69725882T2 (de) * 1996-07-05 2004-07-29 Branton, Philip E., St. Lambert Adenovirus e4 proteine für induktion von zelltod
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP0937150A2 (de) * 1996-09-25 1999-08-25 Novartis AG Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
CA2283253A1 (en) * 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
WO1998049321A2 (en) 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
WO1998059063A2 (en) 1997-06-23 1998-12-30 University Of Saskatchewan Bovine adenovirus type 3 genome
EP1049767B1 (de) 1998-01-08 2005-08-17 Aventis Pharmaceuticals Inc. Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
CA2319212A1 (en) * 1998-02-17 1999-08-19 Genzyme Corporation Methods for purified aav vector production
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
GB9811171D0 (en) * 1998-05-22 1998-07-22 Royal Free Hosp School Med Viral vector
GB9811172D0 (en) * 1998-05-22 1998-07-22 Royal Free Hosp School Med Virus production
US6458586B1 (en) 1998-11-02 2002-10-01 University Of Saskatchewan Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
JP2002541264A (ja) 1999-04-08 2002-12-03 ユーエイビー・リサーチ・ファウンデーション 冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
PT1290023E (pt) 2000-03-31 2011-01-05 Aventis Pharma Inc Factor indutor do factor nuclear kb
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
DE10044384A1 (de) * 2000-09-08 2002-04-18 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
WO2002053761A2 (en) 2000-12-28 2002-07-11 Wyeth Recombinant protective protein from $i(streptococcus pneumoniae)
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
AU2002332736A1 (en) * 2001-08-30 2003-03-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of New adenovirus type 7 vectors
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
EP1497440B1 (de) * 2002-04-25 2008-08-20 Crucell Holland B.V. Stabile adenovirale vektoren und methoden für deren vermehrung
EP1997913A1 (de) 2002-05-15 2008-12-03 Integragen Menschliches Adipositas-Suszeptibilitäsgen und Verwendungen davon
EP1506286B1 (de) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralisierung eines menschlichen anti-igfr-antikörpers
US20040106194A1 (en) * 2002-08-22 2004-06-03 Bett Andrew J. Methods for propagating adenovirus and virus produced thereby
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20080124360A1 (en) 2003-01-24 2008-05-29 Seggern Daniel J Von Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005012537A2 (en) * 2003-07-25 2005-02-10 Genvec, Inc. Adenoviral vector-based vaccines
DE602004021186D1 (de) 2003-08-22 2009-07-02 Integragen Sa Menschliches autismus-suszeptibilitätsgen und verwendungen davon
DE602004025726D1 (de) 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
ATE424469T1 (de) 2004-07-01 2009-03-15 Integragen Sa Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
AU2005274948B2 (en) 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
EP1784493A2 (de) * 2004-09-01 2007-05-16 The Government of the United States of America as Represented by The Department of Health and Human Services Adenovirale vektoren mit der fähigkeit zum umwandeln von apcs, mögliche verwendung bei immunantworterzeugung
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
DE602006017045D1 (de) 2005-03-24 2010-11-04 Integragen Sa Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
MX2008000985A (es) 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
BRPI0618441B8 (pt) 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
WO2007104792A2 (en) * 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP1835036A1 (de) 2006-03-16 2007-09-19 Exonhit Therapeutics SA Zusammensetzungen und Methoden zur Nachweis und Behandlung von Krebs
PL2829551T3 (pl) 2006-10-19 2018-04-30 Csl Limited Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
AU2007319605B2 (en) 2006-10-19 2011-02-17 Csl Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20080248060A1 (en) * 2007-01-09 2008-10-09 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP2027868A1 (de) 2007-08-24 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von SCO-Spondin zur Hemmung oder Verhinderung von durch Zelltod-Rezeptor-Liganden vermittelter Apoptose
EP2238170B1 (de) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antikörper gegen humanes cd39 und ihre verwendung zur hemmung der regulatorischen t-zell-aktivität
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
MX2011004755A (es) 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
EP2199387A1 (de) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serinproteasederivate und deren Verwendung zur Vorbeugung und/oder Behandlung von Blutgerinnungsstörungen
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
EP3002296B1 (de) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla-antikörper und ihre verwendung
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
EP2427205A2 (de) 2009-05-04 2012-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Par2-agonisten zur verwendung bei der behandlung oder prävention von infektionen mit dem grippevirus typ a
EP2427497B1 (de) 2009-05-07 2016-12-07 Stallergenes Verwendung von igg1-immunoglobulinen und/oder liganden des cd32-rezeptors zur behandlung entzündlicher krankheiten und ereignisse über die schleimhaut
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011048443A1 (en) 2009-10-20 2011-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal exocytosis inhibiting peptides derived from c subunit of v-atpase and cosmetic and pharmaceutical compositions containing said peptides
WO2011053699A1 (en) 2009-10-30 2011-05-05 Abbott Laboratories Sorf constructs and multiple gene expression
KR20120139672A (ko) 2009-11-09 2012-12-27 젠벡, 인코포레이티드 원숭이 아데노바이러스 벡터의 증식 방법
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
US8735171B2 (en) 2010-01-13 2014-05-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Promyelocytic leukemia protein as a redox sensor
KR20110103119A (ko) * 2010-03-12 2011-09-20 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
EP2547362B1 (de) 2010-03-17 2021-08-25 Cornell University Unterbrochener impfstoff auf adenovirusbasis gegen drogenmissbrauch
LT2555789T (lt) 2010-04-08 2020-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibuojantys peptidai, kilę iš trem tipo transkripto 1 (tlt-1), ir jų naudojimas
EP2575853B1 (de) 2010-05-25 2016-08-24 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung einer frühzeitigen nahrungsaufnahmestörung bei einem patienten
EP2590669B1 (de) 2010-07-09 2016-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Behandlung von krankheiten im zusammenhang mit degenerativen netzhautstörungen
US9040671B2 (en) 2010-07-23 2015-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for cancer management targeting Co-029
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9132173B2 (en) 2010-10-15 2015-09-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
EP2654789B1 (de) 2010-12-22 2018-05-30 Orega Biotech Antikörper gegen humanes cd39 und ihre verwendung
EP2658869B1 (de) 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenbindende formate zur verwendung in therapeutischen behandlungen oder diagnosetests
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
WO2012120131A1 (en) 2011-03-09 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for generating cell microparticles
WO2012120129A1 (en) 2011-03-10 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
EP3147297B1 (de) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gegen icos gerichtete antikörper und verwendungen davon
NO2707391T3 (de) 2011-05-13 2018-04-07
JP2014516960A (ja) 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6166258B2 (ja) 2011-06-15 2017-07-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ブレビバクテリウム・オーランチアカム（Ｂｒｅｖｉｂａｃｔｅｒｉｕｍａｕｒａｎｔｉａｃｕｍ）から単離されたポリペプチド及び癌の治療を目的とするその使用
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
EP2543677A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543678A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543679A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
FR2979346B1 (fr) 2011-08-23 2013-09-27 Univ Joseph Fourier Nanocorps anti-vcam-1
US20140235492A1 (en) 2011-09-20 2014-08-21 Institut National De La Sante Et De La Recherche Medicate (Inserm) Methods for preparing single domain antibody microarrays
CN103987726B (zh) 2011-10-05 2017-10-03 金维克有限公司 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
JP6757120B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2013174835A1 (en) 2012-05-22 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a candidate compound for its pharmacology on a nuclear receptor
EP2855678B1 (de) 2012-05-25 2017-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur auswahl von bindemitteln mittels phagendisplay und maskierter auswahl
HK1210475A1 (en) 2012-05-29 2016-04-22 Genvec, Inc. Herpes simplex virus vaccine
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
EP2692732A1 (de) 2012-08-03 2014-02-05 Stallergenes S.A. Neues Allergen aus Kreuzkrautpollen und Verwendung davon
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
AU2013311606B2 (en) 2012-09-07 2017-10-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) Trem-Like Transcript 1 (TLT-1) and uses thereof
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
AU2013328550B2 (en) 2012-10-12 2017-10-05 University Of Leicester CSN5 polypeptides and uses thereof for screening therapeutic agents
EP2733153A1 (de) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
US11013783B2 (en) 2012-12-26 2021-05-25 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Anti-inflammatory peptides and methods for treating inflammatory diseases
EP2749289A1 (de) 2012-12-26 2014-07-02 Institut National De La Recherche Agronomique (INRA) Entzündungshemmende Peptide
HK1210713A1 (en) 2012-12-27 2016-05-06 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
EP2970398B1 (de) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Rsv-f-prefusionsproteine und deren verwendung
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
KR101606910B1 (ko) 2013-03-29 2016-04-04 충북보건과학대학교 산학협력단 아데노바이러스 벡터 생산용 ａ５４９ 기반 세포주
WO2014207173A1 (en) 2013-06-27 2014-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
EP2824176A1 (de) 2013-07-11 2015-01-14 Siamed'xpress Verfahren zur Herstellung von sialylierten therapeutischen Proteinen
HK1225258B (en) 2013-08-08 2017-09-08 Global Bio Therapeutics, Inc. Clamping device for minimally invasive surgery
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
JP2016537995A (ja) 2013-11-05 2016-12-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新しいアルツハイマー病動物モデル
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
RU2677997C2 (ru) 2014-01-20 2019-01-22 Санофи Новый полипептид системы цитохрома р450 с повышенной ферментной активностью
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
ES2796857T3 (es) 2014-04-17 2020-11-30 Inst Nat Sante Rech Med Polipéptidos y usos de los mismos para reducir la motilidad celular mediada por CD95
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
EP2974735A1 (de) 2014-07-15 2016-01-20 Institut National De La Recherche Agronomique (INRA) Entzündungshemmende Eigenschaften eines Oberflächenproteins aus Propionibakterium freudenreichii
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016103238A1 (en) 2014-12-24 2016-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus f proteins and their use
DK3247388T3 (da) 2015-01-20 2025-12-22 Us Health Rekombinant human/bovin parainfluenzavirus 3 (b/hpiv3), der udtrykker et kimærisk rsv/bpiv3 f-protein, og anvendelser deraf
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11040113B2 (en) 2015-03-23 2021-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
EP3091033A1 (de) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3-antikörper und verwendungen davon
US20180125947A1 (en) 2015-05-20 2018-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of retinal detachment
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
JP2018525029A (ja) 2015-07-07 2018-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） ミオシン１８ａに対する特異性を有する抗体およびその使用
EP4137150A1 (de) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury-deletionsmutanten, nichthefevektoren zur codierung von brachyury-deletionsmutanten und verwendung davon
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
WO2017046200A1 (en) 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
DK3353196T5 (da) 2015-09-22 2024-09-30 Inst Nat Sante Rech Med Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
KR20180063885A (ko) 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
WO2017050955A1 (en) 2015-09-24 2017-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Agents capable of inhibiting the binding between leptin and vegf165
PT3405215T (pt) 2016-01-19 2022-09-20 Univ California Métodos para o tratamento da doença de danon e outros transtornos da autofagia
WO2017139392A1 (en) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
MX2018010295A (es) 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CN109641955B (zh) 2016-03-22 2022-07-08 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
FI3436593T3 (fi) 2016-03-28 2023-03-16 Ultragenyx Pharmaceutical Inc Adenoviruksen lämpöinaktivointimenetelmiä
WO2018013705A1 (en) * 2016-07-12 2018-01-18 Dimension Therapeutics Use of glucocorticoid analogs to enhance recombinant adeno-associated virus yield
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
ES3041722T3 (en) 2016-07-29 2025-11-14 Inst Nat Sante Rech Med Antibodies targeting tumor associated macrophages and uses thereof
US20200165302A1 (en) 2016-09-14 2020-05-28 Université Catholique de Louvain Modified vsv-g and vaccines thereof
NZ751966A (en) 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New promoters
WO2018057441A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
MX2019003161A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion orf70 de ehv.
CA3036310A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
PL3526321T3 (pl) 2016-10-14 2025-04-28 Ultragenyx Pharmaceutical Inc. Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
CA3080270A1 (en) 2016-10-25 2018-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
US10960070B2 (en) 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
FR3058143B1 (fr) 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
WO2018089527A1 (en) 2016-11-09 2018-05-17 Intrexon Corporation Frataxin expression constructs
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
JP7618386B2 (ja) 2017-01-30 2025-01-21 ブレインヴェクティス ポリグルタミン反復脊髄小脳失調症の処置におけるコレステロール２４－ヒドロキシラーゼ（ｈｙｄｒｏｌａｓｅ）のための発現ベクター
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
WO2018175775A1 (en) 2017-03-22 2018-09-27 Dimension Therapeutics Cell culture methods involving hdac inhibitors or rep proteins
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
WO2018178051A1 (en) 2017-03-28 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction
EP3388072A1 (de) 2017-04-10 2018-10-17 Universität Leipzig Ubichinonunabhängige cytoplasmische dihydroorotat-dehydrogenase zur verwendung als arzneimittel
WO2018208960A1 (en) 2017-05-09 2018-11-15 Dimension Therapeutics, Inc. Scalable method for producing transfection reagents
FI3638776T3 (fi) 2017-06-14 2025-12-09 Univ Dresden Tech Menetelmiä ja välineitä genomien geneettiseen muokkaamiseen hyödyntäen suunnittelu-DNA:ta rekombinoivia entsyymejä
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
WO2019038420A1 (en) 2017-08-25 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
KR102764182B1 (ko) 2017-09-21 2025-02-07 임체크 테라퓨틱스 Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
EP3697908A1 (de) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP3703723A4 (de) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. Onkolytischer plattformvektor zur systemischen abgabe
KR20250136930A (ko) 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
JP7429192B2 (ja) 2018-04-06 2024-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
MX2020011386A (es) 2018-04-27 2021-01-29 Spacecraft Seven Llc Terapia genica para la degeneracion del snc.
DK3807316T3 (da) 2018-06-18 2024-07-29 Innate Pharma Sammensætninger og fremgangsmåder til behandling af cancer
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
KR102918544B1 (ko) 2018-07-12 2026-01-27 로켓 파마슈티컬스, 리미티드 다논병을 치료하기 위한 유전자 요법 벡터
EP3870703A1 (de) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinantes gp120-protein mit v1-schleifendeletion
US20220054597A1 (en) 2018-10-29 2022-02-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
WO2020148338A1 (en) 2019-01-15 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
JP7652705B2 (ja) 2019-03-20 2025-03-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に対する特異性を有する抗体及びその使用
EP3942026A1 (de) 2019-03-22 2022-01-26 Université de Paris Neue inhibitoren der lrrk2/pp1-interaktion
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
EP3972997A1 (de) 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Neuartige anti-cd25-antikörper
JP7624410B2 (ja) 2019-05-21 2025-01-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル レット症候群の治療におけるコレステロール ２４－ヒドロラーゼのための発現ベクター
EP3986453A1 (de) 2019-06-20 2022-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Konformationale anti-protease-nexin-1-einzeldomänenantikörper und verwendungen davon
EP3997225A1 (de) 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von epilepsie
EP3999540A1 (de) 2019-07-16 2022-05-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifizität für cd38 und verwendungen davon
WO2021009299A1 (en) 2019-07-17 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
WO2021023624A1 (en) 2019-08-02 2021-02-11 Orega Biotech Novel il-17b antibodies
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021028837A1 (en) 2019-08-13 2021-02-18 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
EP4025206A1 (de) 2019-09-02 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und zusammensetzungen zur behandlung von krankheiten im zusammenhang mit pax6-mangel
JP7588139B2 (ja) 2019-09-04 2024-11-21 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 慢性閉塞性肺疾患の急性増悪の処置のためのｉｌ２０－ｒｂに特異的な抗体及びその使用
WO2021048171A1 (en) 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
AU2020356334A1 (en) 2019-09-24 2022-03-31 Université Catholique de Louvain Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors
EP4034560A1 (de) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müller-hemmungssubstanz-antikörper und verwendungen davon
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
EP3812008A1 (de) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-kompetitiver antagonistischer antikörper
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
US20230016983A1 (en) 2019-11-19 2023-01-19 lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Antisense oligonucleotides and thier use for the treatment of cancer
JP2023502712A (ja) 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
EP4065600A1 (de) 2019-11-25 2022-10-05 Cornell University Apoe-gentherapie
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
EP4090365A1 (de) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Antigenbindende proteine, die spezifisch prame binden
AU2021213735A1 (en) 2020-01-30 2022-09-22 Umoja Biopharma, Inc. Bispecific transduction enhancer
WO2021163365A1 (en) 2020-02-11 2021-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 vaccine
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
WO2021222639A2 (en) 2020-04-29 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant human metapneumovirus f proteins and their use
CA3180683A1 (en) 2020-05-12 2021-11-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
KR20230030644A (ko) 2020-06-29 2023-03-06 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드
KR20230043869A (ko) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
WO2022035860A2 (en) 2020-08-10 2022-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Replication-competent adenovirus type 4-hiv env vaccines and their use
AU2021335257A1 (en) 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
AU2021379882A1 (en) 2020-11-10 2023-06-29 Sanofi Ceacam5 antibody-drug conjugate formulation
MX2023005570A (es) 2020-11-12 2023-05-29 Inst Nat Sante Rech Med Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
EP4267176A1 (de) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia-impfstoff auf basis des momp-vs4-antigen-targeting auf antigenpräsentierenden zellen
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
US20250282870A1 (en) 2021-01-20 2025-09-11 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
AU2022212952A1 (en) 2021-01-27 2023-08-10 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
US20240124532A1 (en) 2021-01-29 2024-04-18 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
WO2022200469A1 (en) 2021-03-24 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) A dominant negative protein of rad51 for treating cancer
EP4322938A1 (de) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Neues verfahren zur verbesserung der zytotoxizität von nk-zellen
EP4322937A1 (de) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Neues verfahren zur verbesserung der antitumoraktivität von makrophagen
WO2022232648A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4337245A1 (de) 2021-05-13 2024-03-20 Universidade Do Algarve Isolierte oder künstliche nukleotidsequenzen zur verwendung bei neurodegenerativen erkrankungen
PE20240779A1 (es) 2021-07-27 2024-04-17 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a ct45
WO2023012165A1 (en) 2021-08-02 2023-02-09 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
EP4130038A1 (de) 2021-08-03 2023-02-08 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Anti-il-2-antikörper, komplex damit und verwendungen davon
WO2023015186A1 (en) 2021-08-03 2023-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20240366681A1 (en) 2021-08-13 2024-11-07 Triovance Holding Llc A skin substitute composition and methods of producing and using the same
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
EP4426331A1 (de) 2021-11-02 2024-09-11 University of Rochester Tcf7l2-vermittelte remyelinisierung im gehirn
EP4433584A1 (de) 2021-11-15 2024-09-25 Technische Universität Dresden Ortsspezifische rekombinasen zur effizienten und spezifischen genomeditierung
WO2023088968A1 (en) 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
US20250002596A1 (en) 2021-12-01 2025-01-02 Institut National de la Santé et de la Recherche Médicale Neutralizing anti-cd95l monoclonal antibodies
EP4209508A1 (de) 2022-01-11 2023-07-12 Centre national de la recherche scientifique Nanokörpern für das deneddylierende enzym nedp1
JP2025504081A (ja) 2022-02-01 2025-02-06 コーネル・ユニバーシティー フリードライヒ運動失調症に関連する心筋症の治療及び予防のための方法及び医薬組成物
WO2023156437A1 (en) 2022-02-16 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
CN118871466A (zh) 2022-02-25 2024-10-29 Inserm(法国国家健康医学研究院) 阻止金属蛋白酶裂解cd95l的抗体
US20250179210A1 (en) 2022-03-09 2025-06-05 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
EP4490172A1 (de) 2022-03-11 2025-01-15 Institut National De La Sante Et De La Recherche Medicale - Inserm Nukleinsäuresystem zur spezifischen neuprogrammierung von b- und t-zellen und verwendungen davon
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
US20250223326A1 (en) 2022-05-10 2025-07-10 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
EP4551711A1 (de) 2022-07-08 2025-05-14 Cornell University Verfahren und pharmazeutische zusammensetzungen zur behandlung und prävention von morbus alzheimer
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
EP4587473A1 (de) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale Neue anti-itgb8-antikörper und ihre verwendungen
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
EP4601743A1 (de) 2022-10-14 2025-08-20 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung von alpha-synukleinopathien
PT118269A (pt) 2022-10-20 2024-04-22 Univ Aveiro Pkmyt1 for use in regenerative medicine
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
TW202434735A (zh) 2022-11-04 2024-09-01 美商烏莫賈生物製藥股份有限公司 展示黏著分子融合的顆粒
KR20250121163A (ko) 2022-11-04 2025-08-11 우모자 바이오파마 인코포레이티드 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도
EP4646478A1 (de) 2023-01-06 2025-11-12 Institut National de la Santé et de la Recherche Médicale Intravenöse verabreichung von antisense-oligonukleotiden zur behandlung von schmerzen
EP4658303A1 (de) 2023-02-02 2025-12-10 Institut National de la Santé et de la Recherche Médicale Anti-tuberkulose-impfstoff gegen ausgewählte schützende mycobacterium-tuberkulose-antigene auf dendritische zellen
EP4658294A2 (de) 2023-02-02 2025-12-10 University of Rochester Kompetitiver ersatz von gliazellen
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
EP4669330A1 (de) 2023-02-21 2025-12-31 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung des sanfilippo-syndroms vom typ iiib
EP4688843A1 (de) 2023-03-30 2026-02-11 272Bio Limited Gnrh-bindende polypeptide und verwendungen davon
WO2024220719A1 (en) 2023-04-18 2024-10-24 Crystal Ronald G Modified aav capsids for gene delivery
WO2024220722A1 (en) 2023-04-18 2024-10-24 Cornell University Compositions and methods for tissue- specific expression of gene therapies
CN121335984A (zh) 2023-04-18 2026-01-13 康奈尔大学 用于治疗和预防阿尔茨海默病的方法和apoe药物组合物
EP4713467A1 (de) 2023-05-15 2026-03-25 Umoja Biopharma, Inc. Lentivirale verabreichung von chimären anti-cd20-antigenrezeptoren
EP4713371A1 (de) 2023-05-17 2026-03-25 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d-antikörper
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use
EP4724809A2 (de) 2023-06-08 2026-04-15 Cornell University Satseq: modulares system zur kopplung von sättigungsmutagenese, dna-barcodierung und tiefer sequenzierung
EP4731681A1 (de) 2023-06-23 2026-04-29 Imcheck Therapeutics Bispezifische antikörper gegen btn3a und die pd-1/pd-l1-hemmende achse
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025021839A1 (en) 2023-07-25 2025-01-30 Institut National de la Santé et de la Recherche Médicale Method to treat metabolic disorders
CN121358777A (zh) 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025045915A1 (en) 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
US12410436B2 (en) * 2023-10-31 2025-09-09 Lonza Houston, Inc. Adeno-associated virus (AAV) producer cell lines
EP4563586A1 (de) 2023-11-28 2025-06-04 Université Paris Cité Neue inhibitoren der lrrk2/pp1-interaktion
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025157848A1 (en) 2024-01-23 2025-07-31 Institut National de la Santé et de la Recherche Médicale Methods for the intravenous treatment of sanfilippo syndrome type iiib
WO2025171001A1 (en) 2024-02-06 2025-08-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for improved production of aav viral vectors
WO2025186293A1 (en) 2024-03-06 2025-09-12 Institut National de la Santé et de la Recherche Médicale Chmp2b mutants for use for treating infection
WO2025202674A1 (en) 2024-03-27 2025-10-02 Institut National de la Santé et de la Recherche Médicale Langerhans cells targeting hiv-1 vaccines
WO2025215206A1 (en) 2024-04-12 2025-10-16 Institut National de la Santé et de la Recherche Médicale Activator of primary cilia to treat cognitive dysfunctions or ciliopathies
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025233432A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025247913A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Anti-ifn-omega1 monoclonal antibodies
WO2025247918A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247917A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES
WO2025247924A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025252857A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale Il-15 muteins with ph-dependent binding for il-15ralpha
WO2025252855A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2025262304A1 (en) 2024-06-20 2025-12-26 Sanofi Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers
WO2026003242A1 (en) 2024-06-28 2026-01-02 Institut National de la Santé et de la Recherche Médicale Dendritic cells-targeting vaccine against hbv infection
WO2026030724A1 (en) 2024-08-01 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 vaccine
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders
WO2026033136A1 (en) 2024-08-09 2026-02-12 Immatics Biotechnologies Gmbh Advanced treatment modalities for anti-prame tcr-engineered immune cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1024198A3 (de) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenovirenvectors zur Gentherapie der Hämophilien
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
WO1996018418A1 (en) * 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells

Also Published As

Publication number Publication date
MX9704552A (es) 1997-10-31
EP0805868A1 (de) 1997-11-12
CZ294969B6 (cs) 2005-04-13
HUP9702404A3 (en) 1999-10-28
HUP9702404A2 (hu) 1998-04-28
FI973055A0 (fi) 1997-07-18
CA2210168A1 (fr) 1996-07-25
SK99097A3 (en) 1998-02-04
IL116816A (en) 2003-05-29
IL116816A0 (en) 1996-05-14
HU222191B1 (hu) 2003-05-28
WO1996022378A1 (fr) 1996-07-25
KR19980701512A (ko) 1998-05-15
BR9606971A (pt) 1997-11-04
KR100510822B1 (ko) 2005-12-19
CZ230697A3 (en) 1997-10-15
FI973055A7 (fi) 1997-07-18
NO973332L (no) 1997-07-18
US6127175A (en) 2000-10-03
NO320382B1 (no) 2005-11-28
NO973332D0 (no) 1997-07-18
JPH11504502A (ja) 1999-04-27
AU717253B2 (en) 2000-03-23
AU4544396A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
FI973055L (fi) Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi
DE69619111D1 (de) Wärmezellen
DE69602122D1 (de) Flache Zelle
NO981988L (no) Celleinneslutningsstruktur
DE69831948D1 (de) Selbständiges zellwachstumssystem
DE69603416D1 (de) Elektrochemischer Immunobiosensor
NO976058L (no) Rekombinant mistellectin
DK0748583T3 (da) Mejetærsker
DE69601275D1 (de) Stromabnehmerelemente
DE69627291D1 (de) Elektrodensystem
DE69728382D1 (de) Zellenausrichter
DE59602409D1 (de) Elektrolytzelle
DE69617382D1 (de) Stromspeicherzelle
DE69727301D1 (de) Driftzelle
DE59605552D1 (de) Oberbaukonstruktion
FI973269A7 (fi) Galvanosorptinen reaktiokenno
AU7362398A (en) B cell receptor associated proteins
DE69620144D1 (de) Stromspeicherzelle
DE69617383D1 (de) Stromspeicherzelle
NO951705D0 (no) All-solid state reference electrode
GB9621492D0 (en) Novel cell surface protein compounds
ATA203894A (de) Rekombinante dna moleküle
FI961467A0 (fi) Sähkökemiallinen menetelmä
ZA96454B (en) Cells for the production of recombinant adenoviruses
KR960033777U (ko) 바이오 타일

Legal Events

Date Code Title Description
MA Patent expired